TriangleNCT00392327 · OUTCOME
Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percent Probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 5 years
What was measured
The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. Data below represents all molecular subgroups combined.
Analysis population: Eligible medulloblastoma patients are included.
Groups in this outcome
Regimen A (Medulloblastoma Patients)
Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)
Regimen B (Medulloblastoma Patients)
Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)
Regimen C (Medulloblastoma Patients)
Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)
Regimen D (Medulloblastoma Patients)
Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)
| Group | Source count |
|---|---|
| Regimen A (Medulloblastoma Patients) | 87 |
| Regimen B (Medulloblastoma Patients) | 89 |
| Regimen C (Medulloblastoma Patients) | 53 |
| Regimen D (Medulloblastoma Patients) | 56 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Regimen A (Medulloblastoma Patients) | 57.5 | Not reported | 43.6 | 71.4 | Not reported |
| Regimen B (Medulloblastoma Patients) | 65.3 | Not reported | 52.0 | 78.6 | Not reported |
| Regimen C (Medulloblastoma Patients) | 60.3 | Not reported | 47.0 | 73.6 | Not reported |
| Regimen D (Medulloblastoma Patients) | 70.9 | Not reported | 57.8 | 84.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 43.6
- upper Limit
- 71.4
- value
- 57.5
- group Id
- OG001
- lower Limit
- 52.0
- upper Limit
- 78.6
- value
- 65.3
- group Id
- OG002
- lower Limit
- 47.0
- upper Limit
- 73.6
- value
- 60.3
- group Id
- OG003
- lower Limit
- 57.8
- upper Limit
- 84.0
- value
- 70.9
- denoms
- counts
- group Id
- OG000
- value
- 87
- group Id
- OG001
- value
- 89
- group Id
- OG002
- value
- 53
- group Id
- OG003
- value
- 56
- units
- Participants
- description
- The Kaplan-Meier method will be used to estimate 5-year EFS, defined as the time from study enrollment to disease progression or recurrence, second malignant neoplasm, or death from any cause, or to date of last contact. Estimates are reported with 95% confidence intervals. Data below represents all molecular subgroups combined.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)
- id
- OG000
- title
- Regimen A (Medulloblastoma Patients)
- description
- Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)
- id
- OG001
- title
- Regimen B (Medulloblastoma Patients)
- description
- Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)
- id
- OG002
- title
- Regimen C (Medulloblastoma Patients)
- description
- Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)
- id
- OG003
- title
- Regimen D (Medulloblastoma Patients)
- param Type
- NUMBER
- population Description
- Eligible medulloblastoma patients are included.
- reporting Status
- POSTED
- time Frame
- Up to 5 years
- title
- Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma
- type
- PRIMARY
- unit Of Measure
- Percent Probability
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice